Alm. Brand A/S
22.9.2026 14:00:00 CEST | Globenewswire | Press release
Alm. Brand A/S – Weekly report on share buybacks
Alm. Brand A/S – Weekly report on share buybacks
Transactions during 15 September 2026 – 21 September 2026
On 7 May 2026, Alm. Brand A/S announced a share buy-back program of up to DKK 593 million, as described in company announcement no. 23/2026.
The program is carried out in accordance with the Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulations.
The following transactions were made under the share buy-back program 15 September – 21 September 2026:
| Number of shares bought | Average purchase price | Amount (DKK) | |
| Accumulated, last announcement 15 September 2026 16 September 2026 17 September 2026 18 September 2026 21 September 2026 | 12,127,667 59,000 255,000 204,000 250,000 259,000 | 16.37 17.12 17.19 17.24 17.16 17.43 | 198,486,915 1,010,086 4,384,215 3,517,858 4,290,900 4,513,826 |
| Total, 15 September – 21 September 2026 | 1,027,000 | 17.25 | 17,716,885 |
| Accumulated under the program | 13,154,667 | 16.44 | 216,203,800 |
With the transactions stated above Alm. Brand A/S holds a total of 45,891,339 own shares, corresponding to 3.27% of the total number of outstanding shares.
Contact
Please direct any questions regarding this announcement to:
Investors and equity analysts:
VP, Head of Investor Relations & ESG
Mads Thinggaard
Mobile no, +45 2025 5469
Attachments
- Alm Brand_Share buyback 15 September - 21 September 2026
- AS 52 2026 - Transactions under share buyback program
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
SK pharmteco Inc.22.9.2026 15:03:00 CEST | Press release
SK pharmteco and GEMMABio Expand Rare Disease Manufacturing Collaboration Following Important Spinal Muscular Atrophy (SMA) Clinical Trial Milestone
Tenneco22.9.2026 15:00:53 CEST | Press release
Tenneco to Showcase Latest Railway Braking, Sliding Bearing and Systems Protection Solutions at InnoTrans 2026
AIM ImmunoTech Inc.22.9.2026 14:55:00 CEST | Press release
AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib
Nykredit Realkredit A/S22.9.2026 14:45:00 CEST | Pressemeddelelse
Nykredit Realkredit A/S: Ledende medarbejdere og disses nærtstående transaktioner
Nykredit Realkredit A/S22.9.2026 14:45:00 CEST | Pressemeddelelse
Nykredit Realkredit A/S: Ledende medarbejdere og disses nærtstående transaktioner
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom